Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTRibute-PN
2018-004670-10Phase 3Terminated
- Sponsor
- Eidos Therapeutics
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in familial amyloid polyneuropathy (FAP) comparing AG10 with Placebo (2 arms). Primary endpoint: Change from baseline to Month 18 in mNIS+7 score. Started May 2020; status: terminated.
02
Drugs
acoramidis
03
Conditions
familial amyloid polyneuropathy (FAP)
Beyond the preview
Go deeper on 2018-004670-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004670-10.